NASDAQ: GHRS - GH Research PLC

Lønnsomhet i seks måneder: -40.22%
Sektor: Healthcare

Kampanjeplan GH Research PLC

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.

flere detaljer
The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2021-06-25
ISIN IE000GID8VI0
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.ghres.com
Цена ао 11.09
Prisendring per dag: -2.47% (7.3)
Prisendring per uke: +3.94% (6.85)
Prisendring per måned: -23.28% (9.28)
Prisendring over 3 måneder: +3.49% (6.88)
Prisendring over seks måneder: -40.22% (11.91)
Prisendring per år: +22.76% (5.8)
Prisendring over 3 år: -70.78% (24.37)
Prisendring over 5 år: 0% (7.12)
Prisendring over 10 år: 0% (7.12)
Prisendring siden begynnelsen av året: -20.62% (8.97)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 1.3 9
P/E 0 0
EV/EBITDA -5.09 0
Total: 3.38

Effektivitet

Navn Betydning Karakter
ROA, % -15.73 0
ROE, % -16.25 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0084 10
Total: 9.4

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 13175.16 10
Lønnsomhet EPS, % 6062.78 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
BVF Inc. 10400158 19.99
RA Capital Management, L.P. 5587333 10.74
RTW Investments LP 3327129 6.39
FMR, LLC 3136869 6.03
Lynx1 Capital Management Lp 1838617 3.53
VR Adviser, LLC 1318327 2.53
Verition Fund Management, LLC 1162485 2.23
Cormorant Asset Management, LP 593043 1.14
Deep Track Capital, LP 499400 0.96
5AM Venture Management, LLC 404404 0.78

ETF Dele, % Lønnsomhet for året, % Utbytte, %
AdvisorShares Psychedelics ETF 4.2406 845.99 0.20
SPDR S&P International Small Cap ETF 0.01104 8.94 3.10348



Veileder Stillingstittel Betaling Fødselsår
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board N/A 1969 (56 år)
Mr. Magnus Halle Co-Founder & MD of Ireland N/A 1997 (28 år)
Ms. Julie Ryan F.C.A. Vice President of Finance N/A 1986 (39 år)
Mr. Aaron Cameron M.B.A. Chief Operating Officer N/A 1985 (40 år)
Dr. Velichka Valcheva M.D. Chief Executive Officer N/A 1975 (50 år)

Adresse: Ireland, Dublin D RY, Joshua Dawson House - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.ghres.com